Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (101-110 of 327) with videos related to

Pageof 33
Sort By:
Melanoma Research|May 5, 2011
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanomaErin R DeRose, Alexander Pleet, Wei Wang, et al.
The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 23, 2024
Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanomaKavita Mistry, Sophia Zhao, Ian Strohbehn, et al.
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and immune checkpoint inhibitors: initial considerationsRyan J Sullivan, Douglas B Johnson, Brian I Rini, et al.
Journal of Neuro-Oncology|February 18, 2018
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicityRifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, et al.
Seminars in Arthritis and Rheumatism|November 15, 2024
Musculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritisMazen Nasrallah, Greg Challener, Sara Schoenfeld, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2021
Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrantsLauren E Stopfer, Aaron S Gajadhar, Bhavin Patel, et al.
Journal of Translational Medicine|April 22, 2023
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022Paolo A Ascierto, Renier Brentjens, Samir N Khleif, et al.
Nature Reviews. Clinical Oncology|February 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalizationDouglas B Johnson, Amin H Nassar, Ayesha Aijaz, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignanciesBoaz Mendzelevski, Georg Ferber, Filip Janku, et al.
Pageof 33

Showing results (101-110 of 327) with videos related to

Sort By:
Pageof 33
Melanoma Research|May 5, 2011
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanomaErin R DeRose, Alexander Pleet, Wei Wang, et al.
The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 23, 2024
Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanomaKavita Mistry, Sophia Zhao, Ian Strohbehn, et al.
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and immune checkpoint inhibitors: initial considerationsRyan J Sullivan, Douglas B Johnson, Brian I Rini, et al.
Journal of Neuro-Oncology|February 18, 2018
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicityRifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, et al.
Seminars in Arthritis and Rheumatism|November 15, 2024
Musculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritisMazen Nasrallah, Greg Challener, Sara Schoenfeld, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2021
Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrantsLauren E Stopfer, Aaron S Gajadhar, Bhavin Patel, et al.
Journal of Translational Medicine|April 22, 2023
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022Paolo A Ascierto, Renier Brentjens, Samir N Khleif, et al.
Nature Reviews. Clinical Oncology|February 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalizationDouglas B Johnson, Amin H Nassar, Ayesha Aijaz, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignanciesBoaz Mendzelevski, Georg Ferber, Filip Janku, et al.
Pageof 33